{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T04:22:53Z","timestamp":1769228573793,"version":"3.49.0"},"reference-count":178,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.critrevonc.2015.03.002","type":"journal-article","created":{"date-parts":[[2015,3,14]],"date-time":"2015-03-14T16:33:42Z","timestamp":1426350822000},"page":"222-242","source":"Crossref","is-referenced-by-count":20,"title":["Chronic myelomonocytic leukemia: Forefront of the field in 2015"],"prefix":"10.1016","volume":"95","author":[{"given":"Christopher B.","family":"Benton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziz","family":"Nazha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2015.03.002_bib0895","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1309\/AJCPJ71PTVIKGEVT","article-title":"Myelodysplastic\/myeloproliferative neoplasms","volume":"132","author":"Foucar","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib0900","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/1097-0142(197105)27:5<1221::AID-CNCR2820270530>3.0.CO;2-P","article-title":"Myelomonocytic leukemia: disorderly proliferation of all marrow cells","volume":"27","author":"Saarni","year":"1971","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib0905","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib0910","first-page":"1943","article-title":"Subacute myelo-monocytic leukemia. Study of 27 cases and review of the literature","volume":"48","author":"Zittoun","year":"1972","journal-title":"La semaine des h\u00f4pitaux"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib0915","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0145-2126(00)00088-6","article-title":"Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients","volume":"24","author":"Germing","year":"2000","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib0920","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2141.1975.tb00544.x","article-title":"Chronic myelomonocytic leukaemia","volume":"30","author":"Geary","year":"1975","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib0925","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0145-2126(97)00192-6","article-title":"Problems in the classification of CMML\u2014dysplastic versus proliferative type","volume":"22","author":"Germing","year":"1998","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib0930","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French\u2013American\u2013British (FAB) co-operative group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib0935","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib0940","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","article-title":"The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French\u2013American\u2013British Cooperative Leukaemia Group","volume":"87","author":"Bennett","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib0945","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0145-2126(01)00014-5","article-title":"Dysplastic versus proliferative CMML\u2014a retrospective analysis of 91 patients from a single institution","volume":"25","author":"N\u00f6sslinger","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib0950","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib0955","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0145-2126(00)00159-4","article-title":"Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia\u2014distinct subgroups or two stages of the same disease","volume":"25","author":"Voglov\u00e1","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib0960","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.leukres.2014.09.003","article-title":"Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias","volume":"38","author":"Schuler","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib0965","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2011.08631.x","article-title":"Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia","volume":"153","author":"Bacher","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib0970","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib0975","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2141.1987.tb02291.x","article-title":"Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils: a nonrandom association","volume":"67","author":"Keene","year":"1987","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib0980","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0165-4608(91)90142-H","article-title":"Atypical chronic myelomonocytic leukemia with eosinophilia and translocation (5;12). A new association","volume":"51","author":"Berkowicz","year":"1991","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib0985","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2141.1992.tb06450.x","article-title":"Myelodysplastic syndrome associated with increased bone marrow fibrosis and translocation (5;12)(q33;p12.3)","volume":"82","author":"Lerza","year":"1992","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib0990","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0165-4608(93)90051-M","article-title":"t(5;12)(q31;p12). A clinical entity with features of both myeloid leukemia and chronic myelomonocytic leukemia","volume":"65","author":"Wessels","year":"1993","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib0995","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-8674(94)90322-0","article-title":"Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation","volume":"77","author":"Golub","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1000","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1182\/blood.V91.12.4419","article-title":"Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2)","volume":"91","author":"Ross","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1005","first-page":"307","article-title":"Chronic myelomonocytic leukemia with der(9)t(1;9)(q11;q34) as a sole abnormality","volume":"39","author":"Suh","year":"2009","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2257.1996.tb00738.x","article-title":"A new translocation, t(3;6)(q12;24) associated with chronic myelomonocytic leukaemia and marrow fibrosis","volume":"18","author":"Krishnan","year":"1996","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.0.CO;2-7","article-title":"Novel MLL-CBP fusion transcript in therapy-related chronic myelomonocytic leukemia with a t(11;16)(q23;p13) chromosome translocation","volume":"20","author":"Satake","year":"1997","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cancergencyto.2004.12.009","article-title":"A der(14)t(1;14)(q12;p11) in chronic myelomonocytic leukemia","volume":"160","author":"Djordjevic","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1025","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cancergencyto.2008.04.001","article-title":"A novel variant form of MLL-ELL fusion transcript with t(11;19)(q23;p13.1) in chronic myelomonocytic leukemia transforming to acute myeloid leukemia","volume":"184","author":"Kakihana","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1030","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/leu.2012.109","article-title":"RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation","volume":"26","author":"Ballerini","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1035","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1040","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/ajh.23751","article-title":"Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution","volume":"89","author":"Tang","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1045","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ajh.23846","article-title":"Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study","volume":"89","author":"Wassie","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1050","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2007-05-092304","article-title":"Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS\/MPD, and MDS-derived AML","volume":"111","author":"Gondek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1055","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1182\/blood-2010-07-295857","article-title":"Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies","volume":"117","author":"Tiu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1060","doi-asserted-by":"crossref","first-page":"10349","DOI":"10.1158\/0008-5472.CAN-08-2754","article-title":"250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies","volume":"68","author":"Dunbar","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1065","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1182\/blood-2009-02-205690","article-title":"Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic\/myeloproliferative neoplasms","volume":"113","author":"Jankowska","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1070","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/leu.2009.59","article-title":"Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS\/MPN and AML","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1075","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1080","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/blood-2002-01-0165","article-title":"Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene","volume":"100","author":"Magnusson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1085","series-title":"JAK2 mutation 1849G&gt;T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome\u2013negative CML, and megakaryocytic leukemia","author":"Jelinek","year":"2005"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1090","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1095","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1100","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1105","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/jcp.2009.065904","article-title":"JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia","volume":"62","author":"Pich","year":"2009","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1110","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1517\/13543784.2011.589383","article-title":"A potential role of ruxolitinib in leukemia","volume":"20","author":"Naqvi","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1115","first-page":"2","article-title":"Ruxolitinib chronic myelomonocytic leukemia-associated myelofibrosis: a case report","volume":"1","author":"Ruiz-Arg\u00fcelles","year":"2013","journal-title":"J. Bone Marrow Res."},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1120","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood.V76.6.1214.1214","article-title":"RAS mutations are rare events in Philadelphia chromosome-negative\/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia","volume":"76","author":"Hirsch-Ginsberg","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1125","first-page":"503","article-title":"RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation","volume":"2","author":"Padua","year":"1988","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1130","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2010-12-326058","article-title":"Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1135","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1140","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2141.2009.07697.x","article-title":"Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia","volume":"145","author":"Gelsi-Boyer","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1145","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1150","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","article-title":"Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2 and DNMT3A","volume":"118","author":"Jankowska","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1155","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/leu.2013.97","article-title":"SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML","volume":"27","author":"Laborde","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1160","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.12491","article-title":"Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression","volume":"163","author":"Fernandez-Mercado","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1165","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1182\/blood-2012-05-430876","article-title":"SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes","volume":"120","author":"Visconte","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1170","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ajh.23373","article-title":"Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance","volume":"88","author":"Patnaik","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1175","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.23345","article-title":"FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"88","author":"Daver","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1180","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","article-title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)","volume":"120","author":"Meggendorfer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1185","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/leu.2008.119","article-title":"The myelodysplastic\/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features","volume":"22","author":"Orazi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1190","series-title":"Hematology\/the education program of the American Society of Hematology American Society of Hematology Education Program","first-page":"264","article-title":"Myelodysplastic\/myeloproliferative neoplasms","author":"Cazzola","year":"2011"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1195","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2141.2009.07683.x","article-title":"Leukaemia cutis with chronic myelomonocytic leukaemia","volume":"147","author":"Mahmood","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1200","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1101\/gad.1045603","article-title":"Proapoptotic BID is required for myeloid homeostasis and tumor suppression","volume":"17","author":"Zinkel","year":"2003","journal-title":"Genes Dev"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1205","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/ajh.10108","article-title":"Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes","volume":"70","author":"Boudard","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1210","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00277-009-0835-2","article-title":"Cell cycle and apoptosis regulatory gene expression in the bone marrow of patients with de novo myelodysplastic syndromes (MDS)","volume":"89","author":"Economopoulou","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1215","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1220","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/sj.bjc.6693515","article-title":"Angiogenesis in myelodysplastic syndromes","volume":"81","author":"Pruneri","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1225","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.V96.6.2240","article-title":"Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes","volume":"96","author":"Aguayo","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1230","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/10428190500353083","article-title":"Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category","volume":"47","author":"Wimazal","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1235","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s10735-004-2341-0","article-title":"Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes","volume":"35","author":"Alexandrakis","year":"2004","journal-title":"J Mol Histol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1240","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.leukres.2004.05.002","article-title":"Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes","volume":"29","author":"Alexandrakis","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1245","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1182\/blood.V97.5.1427","article-title":"Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes","volume":"97","author":"Bellamy","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1250","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1255","first-page":"3","article-title":"Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera","volume":"64","author":"Pargade","year":"2006","journal-title":"Ann Biol Clin"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1260","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/1471-2407-8-299","article-title":"Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes","volume":"8","author":"Gelsi-Boyer","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1265","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","article-title":"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia","volume":"106","author":"Levine","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1270","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2012-10-460170","article-title":"GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia","volume":"121","author":"Padron","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1275","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood.V93.6.2043.406k17_2043_2056","article-title":"Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice","volume":"93","author":"MacKenzie","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1280","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias","volume":"121","author":"Itzykson","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1285","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2013.100","article-title":"An evolutionary perspective on chronic myelomonocytic leukemia","volume":"27","author":"Itzykson","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1290","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3324\/haematol.2009.011205","article-title":"TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia","volume":"94","author":"Kosmider","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1295","doi-asserted-by":"crossref","first-page":"14566","DOI":"10.1073\/pnas.1112317108","article-title":"Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice","volume":"108","author":"Ko","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1300","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1182\/blood-2010-12-325241","article-title":"Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies","volume":"118","author":"Li","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1305","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","article-title":"TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis","volume":"20","author":"Quivoron","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1310","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","article-title":"Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation","volume":"20","author":"Moran-Crusio","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1315","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression","volume":"22","author":"Abdel-Wahab","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1320","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.leukres.2013.01.014","article-title":"Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia","volume":"37","author":"Cilloni","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1325","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1073\/pnas.0307203101","article-title":"Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder","volume":"101","author":"Braun","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1330","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1172\/JCI20476","article-title":"Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease","volume":"113","author":"Chan","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1335","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1182\/blood-2010-04-281527","article-title":"Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic\/monocytic precursors in a murine model of chronic myelomonocytic leukemia","volume":"116","author":"Wang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1340","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1172\/JCI74182","article-title":"Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm","volume":"124","author":"Kong","year":"2014","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1345","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1084\/jem.179.3.1047","article-title":"bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages","volume":"179","author":"Lagasse","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1350","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stem cells","volume":"414","author":"Reya","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1355","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1182\/blood-2013-05-500272","article-title":"Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1360","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1084\/jem.20131141","article-title":"Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo","volume":"210","author":"Abdel-Wahab","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1365","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1126\/science.1221711","article-title":"Loss of the tumor suppressor BAP1 causes myeloid transformation","volume":"337","author":"Dey","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1370","doi-asserted-by":"crossref","first-page":"e51228","DOI":"10.1371\/journal.pone.0051228","article-title":"Deletion of TAK1 in the myeloid lineage results in the spontaneous development of myelomonocytic leukemia in mice","volume":"7","author":"Lamothe","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1375","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1172\/JCI45213","article-title":"Transcription intermediary factor 1\u03b3 is a tumor suppressor in mouse and human chronic myelomonocytic leukemia","volume":"121","author":"Aucagne","year":"2011","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1380","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1038\/sj.leu.2401494","article-title":"The Tel-PDGFRbeta fusion gene produces a chronic myeloproliferative syndrome in transgenic mice","volume":"13","author":"Ritchie","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1385","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood-2003-11-3801","article-title":"Complete remission of TEL-PDGFRB-induced myeloproliferative disease in mice by receptor tyrosine kinase inhibitor SU11657","volume":"104","author":"Cain","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1390","doi-asserted-by":"crossref","first-page":"5860","DOI":"10.1182\/blood-2011-02-334425","article-title":"3\u2032UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice","volume":"117","author":"Ikeda","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1395","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1172\/JCI24177","article-title":"Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms","volume":"115","author":"F\u00fctterer","year":"2005","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1400","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3324\/haematol.11051","article-title":"Chronic myelomonocytic leukemia in the light of the WHO proposals","volume":"92","author":"Germing","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1405","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2141.1985.tb07329.x","article-title":"Myelodysplastic syndromes: a scoring system with prognostic significance","volume":"59","author":"Mufti","year":"1985","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1410","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2141.1988.tb04173.x","article-title":"Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival","volume":"68","author":"Worsley","year":"1988","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1415","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood.V74.1.395.395","article-title":"Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients","volume":"74","author":"Sanz","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1420","first-page":"52","article-title":"Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system","volume":"6","author":"Aul","year":"1992","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1425","first-page":"1315","article-title":"Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases","volume":"7","author":"Morel","year":"1993","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1430","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1435","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/1042819042000207271","article-title":"Risk assessment in chronic myelomonocytic leukemia (CMML)","volume":"45","author":"Germing","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1440","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1445","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/cncr.23697","article-title":"Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System","volume":"113","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1450","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0145-2126(02)00021-8","article-title":"Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center","volume":"26","author":"Gonz\u00e1lez-Medina","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1455","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/leu.2013.88","article-title":"Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes","volume":"27","author":"Patnaik","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1460","doi-asserted-by":"crossref","first-page":"S373","DOI":"10.1016\/j.clml.2013.07.074","article-title":"Refined MD Anderson Prognostic Scoring System (MDAPS-R) for chronic myelomonocytic leukemia (CMML)","volume":"13","author":"Takahashi","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1465","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2013-03-491399","article-title":"Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia","volume":"122","author":"Takahashi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1470","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.clml.2014.06.007","article-title":"Monosomal karyotype predicts adverse prognosis in patients diagnosed with chronic myelomonocytic leukemia: a single-institution experience","volume":"15","author":"Alsahlawi","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1475","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1182\/blood-2010-03-274704","article-title":"Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value","volume":"116","author":"Smith","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1480","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3324\/haematol.2009.011205","article-title":"TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia","volume":"94","author":"Kosmider","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1485","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/leu.2009.48","article-title":"RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation","volume":"23","author":"Kuo","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1490","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjh.12756","article-title":"Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review","volume":"165","author":"Patnaik","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1495","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1046\/j.1445-5994.2001.00074.x","article-title":"Response to erythropoietin in chronic myelomonocytic leukaemia","volume":"31","author":"Kerridge","year":"2001","journal-title":"Intern Med J"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1500","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/bmt.2011.141","article-title":"Current status of allogeneic HST for chronic myelomonocytic leukemia","volume":"47","author":"Cheng","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1505","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.bbmt.2010.09.018","article-title":"Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities","volume":"17","author":"Eissa","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1510","first-page":"S241","article-title":"Allogeneic stem cell transplantation in patients with chronic myelomonocytic leukaemia: the impact of WHO classification and of the conditioning regimen on the transplantation outcome","volume":"45","author":"Symeonidis","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1515","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/bmt.2009.375","article-title":"Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience","volume":"45","author":"Krishnamurthy","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1520","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/bmt.2008.366","article-title":"Outcome of allo-SCT for chronic myelomonocytic leukemia","volume":"43","author":"Ocheni","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1525","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.bmt.1705369","article-title":"Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia","volume":"37","author":"Elliott","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1530","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.bbmt.2005.05.008","article-title":"Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia","volume":"11","author":"Kerbauy","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1535","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.bmt.1704472","article-title":"Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative\/BCR-ABL-negative chronic myelogenous leukemia","volume":"33","author":"Mittal","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1540","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2141.2002.03552.x","article-title":"Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"118","author":"Kr\u00f6ger","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1545","doi-asserted-by":"crossref","unstructured":"Jurado M, Deeg H, Storer B, Anasetti C. \u2026 advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable \u2026. \u2026 marrow transplantation, 2002.","DOI":"10.1053\/bbmt.2002.v8.pm11939606"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1550","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1365-2141.2000.02133.x","article-title":"Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation","volume":"110","author":"Zang","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1555","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/sj.bmt.1704381","article-title":"Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome","volume":"33","author":"Depil","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1560","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood.V88.7.2480.bloodjournal8872480","article-title":"A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Fran\u00e7ais des My\u00e9lodysplasies and European CMML Group","volume":"88","author":"Wattel","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1565","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","article-title":"Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1570","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/cncr.22457","article-title":"Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia","volume":"109","author":"Aribi","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1575","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.leukres.2007.08.004","article-title":"Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)","volume":"32","author":"Wijermans","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1580","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1182\/blood-2007-07-103960","article-title":"Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia","volume":"111","author":"Oki","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1585","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2011-05-352039","article-title":"Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase II trial","author":"Braun","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1590","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cncr.25759","article-title":"Activity of azacitidine in chronic myelomonocytic leukemia","volume":"117","author":"Costa","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1595","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.2010.34.4226","article-title":"Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1600","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood.V88.7.2473.bloodjournal8872473","article-title":"Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"88","author":"Beran","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1605","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/10428199809057611","article-title":"Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"31","author":"Beran","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1610","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1999.17.9.2819","article-title":"Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"17","author":"Beran","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1615","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1080\/10428190310001593175","article-title":"Phase I\/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia","volume":"45","author":"Weihrauch","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1620","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/10428190500353943","article-title":"Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes","volume":"47","author":"Raza","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1625","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1021\/jm00113a034","article-title":"Nucleosides and nucleotides. 100. 2\u2032-C-cyano-2\u2032-deoxy-1-beta-d-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside","volume":"34","author":"Matsuda","year":"1991","journal-title":"J Med Chem"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1630","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.2009.25.0209","article-title":"Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome","volume":"28","author":"Kantarjian","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1635","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2009.26.3509","article-title":"Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome","volume":"28","author":"Faderl","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1640","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1053\/j.seminoncol.2011.07.001","article-title":"Treatment of higher-risk myelodysplastic syndrome","volume":"38","author":"Garcia-Manero","year":"2011","journal-title":"Sem Oncol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1645","first-page":"202","article-title":"CMML: a biologically distinct myeloproliferative disease","volume":"2","author":"Cortes","year":"2003","journal-title":"Curr Hematol Rep"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1650","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1002\/cncr.11416","article-title":"Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders","volume":"97","author":"Cortes","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1655","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/cncr.11315","article-title":"Phase II study of SU5416\u2014a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor\u2014in patients with refractory myeloproliferative diseases","volume":"97","author":"Giles","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1660","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2402330","article-title":"Thalidomide for the treatment of patients with myelodysplastic syndromes","volume":"16","author":"Strupp","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1665","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood.V98.4.958","article-title":"Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes","volume":"98","author":"Raza","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1670","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00277-005-1031-7","article-title":"Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes","volume":"84","author":"Candoni","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1675","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/cncr.23789","article-title":"Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia","volume":"113","author":"Raza","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1680","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1002\/cncr.26741","article-title":"A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) or primary myelofibrosis (PMF)","volume":"118","author":"Bejanyan","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1685","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/sj.leu.2404811","article-title":"Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus","volume":"21","author":"Platzbecker","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1690","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2003-12-4333","article-title":"Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid","volume":"104","author":"Kuendgen","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1695","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3324\/haematol.11262","article-title":"Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes","volume":"92","author":"Siitonen","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1700","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1158\/1078-0432.CCR-09-0494","article-title":"Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes","volume":"15","author":"Voso","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1705","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","article-title":"Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes","volume":"111","author":"Garcia-Manero","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1710","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/sj.leu.2404918","article-title":"Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines","volume":"22","author":"Galimberti","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1715","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1200\/JCO.1999.17.11.3631","article-title":"Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development","volume":"17","author":"Rowinsky","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1720","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/leu.2008.156","article-title":"On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"22","author":"Feldman","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1725","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1182\/blood-2002-11-3359","article-title":"Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting","volume":"102","author":"Kurzrock","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1730","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1200\/JCO.2004.08.082","article-title":"Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome","volume":"22","author":"Kurzrock","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1735","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/cncr.25575","article-title":"A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"117","author":"Jabbour","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1740","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1182\/blood-2006-07-035725","article-title":"A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome","volume":"109","author":"Fenaux","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1745","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/sj.leu.2403569","article-title":"Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia","volume":"19","author":"Buresh","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1750","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/cncr.22186","article-title":"Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"107","author":"Quintas-Cardama","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1755","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.leu.2402726","article-title":"Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts","volume":"17","author":"Ribrag","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1760","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.leukres.2014.03.022","article-title":"Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis","volume":"38","author":"Buckstein","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1765","first-page":"1164","article-title":"All-trans retinoic acid in adult chronic myelomonocytic leukemia: results of a pilot study","volume":"10","author":"Cambier","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1770","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00277-008-0536-2","article-title":"Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study","volume":"87","author":"Ravoet","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1775","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1200\/jco.2007.25.18_suppl.7071","article-title":"I study of s-trans, trans-farnesylthiosalicylic acid (FTS), a novel oral Ras inhibitor, in patients with refractory hematologic malignancies","volume":"25","author":"Borthakur","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.03.002_bib1780","first-page":"509","article-title":"Phase II study of the JAK2 inhibitor, INCB018424, In patients with refractory leukemias including post-myeloproliferative disorder (MPD) acute myeloid leukemia (sAML)","volume":"116","author":"Eghtedar","year":"2010","journal-title":"ASH Annu Meet Abstr"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815000499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815000499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T21:16:56Z","timestamp":1717795016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842815000499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":178,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1040842815000499"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.03.002","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}